Claims

1. An aqueous topical ophthalmic pharmaceutical composition comprising apraclonidine and a polymer, wherein the apraclonidine is present at greater than 0.05% (w/v) to no more than 0.2% (w/v).

2. The pharmaceutical composition of claim 1, wherein the apraclonidine is present at 0.06% (w/v) to 0.2% (w/v).

3. The pharmaceutical composition of claim 2, wherein the apraclonidine is present at 0.07% (w/v) to 0.15% (w/v).

4. The pharmaceutical composition of claim 3, wherein the apraclonidine is present at 0.08% (w/v) to 0.125% (w/v).

5. The pharmaceutical composition of claim 1, wherein the apraclonidine is present at 0.125% (w/v).

6. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is a liquid having a viscosity of 1 - 20 cP.

7. The pharmaceutical composition of claim 1, wherein the polymer is selected from the group consisting of methylcellulose, hydroxypropyl methylcellulose, hydroxyethyl-cellulose, carboxymethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, xanthan gum, carbopol, hyaluronic acid, and hydroxypropyl guar.

8. The pharmaceutical composition of claim 7, wherein the polymer is hydroxypropyl methylcellulose.

9. The pharmaceutical composition of claim 8, wherein the polymer is present at 0.3% (w/v).

10. The pharmaceutical composition of claim 1, further comprising an ophthalmically acceptable buffer.

11. The pharmaceutical composition of claim 10, wherein the pharmaceutical composition comprises citric acid and sodium citrate.

12. The pharmaceutical composition of claim 1, further comprising a tonicity adjusting agent in an amount sufficient to cause the pharmaceutical composition to have an osmolarity of 260 to 330 mOsm/kg based on the total weight of the pharmaceutical composition.

13. The pharmaceutical composition of claim 12, wherein the tonicity adjusting agent is sodium chloride.

14. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition has a pH value of 5.8 — 7.8.

15. The pharmaceutical composition of claim 1, further comprising benzalkonium chloride.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition comprises 0.005% (w/v) benzalkonium chloride.

17. Use of the pharmaceutical composition according to claim 1 in the manufacture of a medicament for the treatment of ocular redness in an eye of a subject, wherein a therapeutically effective amount of the pharmaceutical composition is to be administered to the eye of the subject.

18. The use according to claim 17, wherein the pharmaceutical composition comprises apraclonidine in the form of apraclonidine hydrochloride, the apraclonidine hydrochloride is present in an amount equivalent to 0.08 — 0.125% (w/v) apraclonidine free base, hydroxypropyl methylcellulose in an amount of 0.05 — 0.5% (w/v), and a tonicity adjusting agent in an amount sufficient to cause the pharmaceutical composition to have an osmolarity of 260 to 330 mOsm/kg based on the total weight of the pharmaceutical composition, wherein the pharmaceutical composition has a pH 6.3 — 7.3.

19. The use according to claim 18, wherein the pharmaceutical composition further comprises benzalkonium chloride in an amount of 0.005% (w/v).

20. The pharmaceutical composition according to claim 1 for use in therapy.